Krystal Biotech (KRYS) earnings

Krystal Biotech, Inc.· Health Care

Results to: Jun 2026
Latest analysed call: Jun 2026 (Q2 FY26)
Balance sheet to: Dec 2025

Company research is public. Sign in to keep your own companies, notes and cases.

Krystal Biotech earnings: last reported Mon, 3 Aug 2026, for the quarter ended Jun 2026.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

Metric	Value	Change	Basis	Period	Note
Revenue	119 $ million	+24.1% YoY	Quarterly, as filed	Quarter to Jun 2026	Revenue from operations as filed.
Operating margin	49.0 %	+8.0 pts YoY	Operating profit / revenue	Quarter to Jun 2026	For the quarter; a change is in percentage points.
Net profit	54.8 $ million	+42.9% YoY	Quarterly, as filed	Quarter to Jun 2026	Profit after tax as filed.

Source: Inve data from filed results (SEC filings) · to Jun 2026

Price

$320.25 +1.16% · +$3.67

Last close Oct 19, 2026 · US · USD

Performance +68.3% 1Y

1Y: $190.23 on 17 Oct 2025 → $320.25. High $378.15 (29 Jun 2026), low $185.05 (29 Oct 2025).

Previous close: $316.58
52-week range: $185.05 – $378.15
One year: +63.43%

Overview

Symbol: KRYS
Sector: Health Care
Exchange: US
Currency: USD

Financials

What the filings say

Net profit, year on year: +43% (quarter to jun 2026 against jun 2025).

In $ million. Oldest period first.

Line item	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	84	91	88	96	98	107	116	119
Operating profit	22	41	36	39	41	44	54	58
Operating margin	26.8%	45.4%	41.1%	41.0%	42.3%	41.3%	46.1%	49.0%
Profit before tax	30	49	44	47	48	51	61	66
Tax rate	8.7%	6.4%	18.0%	18.1%	−65.5%	−0.5%	9.0%	17.1%
Net profit	27	45	36	38	79	51	56	55
EPS ($ per share)	0.95	—	1.24	1.33	2.74	—	1.91	1.85

Source: Inve data · income statement, quarterly · to Jun 2026

In $ million. Oldest period first.

Line item	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Equity capital	0	0	0	0	0	0	0	0
Reserves	-20	-39	-71	-141	-281	-270	-181	24
Total liabilities	3	6	19	33	36	40	109	114
Fixed assets	3	8	31	112	162	161	155	151
Total assets	116	209	311	626	558	818	1,056	1,334

Source: Inve data · balance sheet · to Dec 2025

In $ million. Oldest period first.

Line item	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from operations	-9	-19	-26	-48	-101	-89	123	201
Cash from investing	-10	-5	-11	-227	-114	83	-163	-58
Cash from financing	74	108	118	348	35	203	27	9
Net cash flow	—	84	81	73	-179	196	-13	151
Capital expenditure	-2	-6	-15	-68	-53	-12	-4	-12
Free cash flow	-12	-25	-41	-116	-154	-101	119	189

Source: Inve data · cash flow · to Dec 2025

Insider filings

174 filings between Dec 4, 2025 and Sep 4, 2026.

Open market

decisions to buy or sell

Purchases

None

No insider bought shares.

Sales

$105.27M

142 sales by 6 insiders

93% filed under a 10b5-1 plan — scheduled in advance, not decided on the day

Compensation

not trading decisions

16: Option exercise — converted options into shares
12: Tax withheld — shares kept back by the company to cover tax

Also filed: 4 gifts.

Who traded

open market only

Insider	Bought	Sold	Last filing
Krishnan Suma	—	$34.27M	Sep 4, 2026
Krishnan Krish S	—	$34.27M	Sep 4, 2026
JANNEY DANIEL	—	$19.40M	Feb 27, 2026
ROSSI DINO A	—	$13.18M	Aug 14, 2026
ROMANO KATHRYN	—	$3.60M	Mar 2, 2026
Thomas John Charles	—	$541.2K	Jun 25, 2026

Latest filings (50)

Date	Insider	What	Shares	Value
Sep 4, 2026	Krishnan Krish S President and CEO	Sale 10b5-1 plan	3,981	$1.42M
Sep 4, 2026	Krishnan Krish S President and CEO	Sale 10b5-1 plan	2,010	$728.9K
Sep 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	3,267	$1.16M
Sep 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	3,180	$1.14M
Sep 4, 2026	Krishnan Krish S President and CEO	Sale 10b5-1 plan	3,297	$1.17M
Sep 4, 2026	Krishnan Krish S President and CEO	Sale 10b5-1 plan	3,357	$1.21M
Sep 4, 2026	Krishnan Krish S President and CEO	Sale 10b5-1 plan	520	$184.4K
Sep 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	3,392	$1.22M
Sep 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	3,962	$1.42M
Sep 4, 2026	Krishnan Krish S President and CEO	Sale 10b5-1 plan	1,358	$495.0K
Sep 4, 2026	Krishnan Krish S President and CEO	Sale 10b5-1 plan	405	$148.5K
Sep 4, 2026	Krishnan Krish S President and CEO	Sale 10b5-1 plan	2,029	$721.5K
Sep 4, 2026	Krishnan Krish S President and CEO	Sale 10b5-1 plan	573	$208.2K
Sep 4, 2026	Krishnan Krish S President and CEO	Sale 10b5-1 plan	3,143	$1.13M
Sep 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	1,992	$722.4K
Sep 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	2,006	$713.3K
Sep 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	1,242	$449.1K
Sep 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	2,320	$836.3K
Sep 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	565	$205.3K
Sep 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	399	$146.3K
Sep 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	826	$301.8K
Sep 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	1,329	$484.4K
Sep 4, 2026	Krishnan Krish S President and CEO	Sale 10b5-1 plan	1,214	$439.0K
Sep 4, 2026	Krishnan Krish S President and CEO	Sale 10b5-1 plan	847	$309.5K
Sep 4, 2026	Krishnan Krish S President and CEO	Sale 10b5-1 plan	2,266	$816.8K
Sep 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	520	$184.4K
Aug 14, 2026	ROSSI DINO A Director	Sale	4,896	$1.62M
Aug 14, 2026	ROSSI DINO A Director	Sale	2,287	$746.9K
Aug 14, 2026	ROSSI DINO A Director	Sale	7,428	$2.45M
Aug 14, 2026	ROSSI DINO A Director	Sale	341	$111.0K
Aug 14, 2026	ROSSI DINO A Director	Gift	3,691	$0
Aug 14, 2026	ROSSI DINO A Director	Sale	1,687	$554.2K
Aug 14, 2026	ROSSI DINO A Director	Sale	40	$13.3K
Aug 14, 2026	ROSSI DINO A Director	Sale	5,226	$1.71M
Aug 14, 2026	ROSSI DINO A Director	Sale	3,095	$1.03M
Jun 25, 2026	Thomas John Charles EVP, General Counsel	Option exercise 10b5-1 plan	1,000	$179.3K
Jun 25, 2026	Thomas John Charles EVP, General Counsel	Sale 10b5-1 plan	1,000	$347.3K
Jun 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	2,801	$868.2K
Jun 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	3,803	$1.17M
Jun 4, 2026	Krishnan Krish S President and CEO	Sale 10b5-1 plan	544	$165.8K
Jun 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	12,729	$3.92M
Jun 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	1,348	$414.0K
Jun 4, 2026	Krishnan Krish S President and CEO	Sale 10b5-1 plan	176	$53.4K
Jun 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	480	$146.8K
Jun 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	400	$122.0K
Jun 4, 2026	Krishnan Krish S President and CEO	Sale 10b5-1 plan	640	$193.4K
Jun 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	247	$74.9K
Jun 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	593	$179.2K
Jun 4, 2026	Krishnan Suma President, R&D	Sale 10b5-1 plan	320	$96.2K
Jun 4, 2026	Krishnan Krish S President and CEO	Sale 10b5-1 plan	40	$12.5K

Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.

Your own record

Start an Inve Case for Krystal Biotech, Inc.

Free account. Everything above stays public.

Write why you follow Krystal Biotech, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other US companies filed under K

All 81 companies under K

US companies A–Z · Earnings calls · US earnings-call directory · US sector analysis · What management promised, and delivered

Krystal Biotech (KRYS) earnings

The figures, each with its period

Performance +68.3% 1Y

Jun 2026 (Q2 FY26) — Aug 3, 2026

Mar 2026 (Q1 FY26) — May 4, 2026

Krystal Biotech earnings calls (KRYS)

What the filings say

Insider filings

Open market

Compensation

Who traded

Start an Inve Case for Krystal Biotech, Inc.

Other US companies filed under K